Best practices and rationale for expanding Medicaid access to continuous glucose monitoring

J Manag Care Spec Pharm. 2024 Oct;30(10-b Suppl):S40-S49. doi: 10.18553/jmcp.2024.30.10-b.s40.

Abstract

Numerous studies have demonstrated that use of continuous glucose monitoring (CGM) significantly improves overall glycemic control and reduces the frequency and severity of hypoglycemic events in individuals treated with intensive insulin, nonintensive insulin, and noninsulin therapies, with reductions in both all-cause and diabetes-related health care resource utilization and lower costs. However, implementation of CGM including prescribing and assessment of the ambulatory glucose profile to make clinical decisions in primary care settings is low. A recent pilot program was initiated at MetroHealth System (Cleveland, Ohio) to implement a CGM integration program for primary care offices throughout the system. Based on the experience and successes from this health system as well as current literature, rationale will be discussed to support the expansion of CGM to individuals enrolled in all Medicaid programs.

MeSH terms

  • Blood Glucose Self-Monitoring*
  • Blood Glucose* / drug effects
  • Continuous Glucose Monitoring
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Health Services Accessibility
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / administration & dosage
  • Insulin / therapeutic use
  • Medicaid*
  • Pilot Projects
  • Primary Health Care
  • United States

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin

Grants and funding

Abbott funded the development and writing of this work.